A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).

NCT Number	NCT07309445
Lead Sponsor	Janssen Research & Development, LLC
Conditions	Non-Muscle Invasive Bladder Neoplasms
Enrollment	150 participants
Start Date	2026-06-12
Primary Completion	2029-03-31 (estimated)
Study Completion	2029-10-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-31